Syros Pharmaceuticals (SYRS) Tops Q1 EPS by 4c, Revenues Beat

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/5/2026

1. NVDA
2. SPY
3. PTC
4. META
5. PCVX
6. USO
7. MSFT
8. AMZN
9. AMD
10. ATH

Go back to Syros Pharmaceuticals (SYRS) Tops Q1 EPS by 4c, Revenues Beat

Syros Reports First Quarter 2020 Financial Results and Highlights Recent Accomplishments and Anticipated Milestones

May 7, 2020 7:30 AM EDT

Completed Enrollment in Phase 2 Trial Cohort Evaluating SY-1425 in RARA-Positive Relapsed or Refractory AML Patients

On Track for 2020 Milestones, Including Clinical Data Readouts for SY-1425 and SY-5609

Well-Funded with Cash Runway into 2022

Management to Host Conference Call at 8:30 a.m. ET Today

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of medicines that control the expression of genes, today reported financial results for the quarter ended March 31, 2020 and... More